- Home
- SNSE
as 07-26-2024 4:00pm EST
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 17.0M | IPO Year: | 2021 |
| Target Price: | $4.33 | AVG Volume (30 days): | 27.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $1.94 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Sensei Biotherapeutics Inc. News
SNSE Breaking Stock News: Dive into SNSE Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
GlobeNewswire
3 months ago
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
3 months ago
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
GlobeNewswire
4 months ago
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
GlobeNewswire
4 months ago
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
GlobeNewswire
4 months ago
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
GlobeNewswire
5 months ago
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
Compare SNSE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNSE Sensei Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.